Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | GYS1 | P13807 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177536 | 0.93 | CSF1R (0.37) | CSF1RLRRK2HIF1AAAK1DGAT1 | |
| SCHEMBL21177449 | 0.86 | TRPV1 (0.38) | CSF1RHIF1AAAK1LIPGHSP90AA1 | |
| SCHEMBL21177199 | 0.85 | CSF1R (0.42) | CSF1RHIF1AAAK1DGAT1LIPG | |
| SCHEMBL21179344 | 0.84 | HIF1A (0.36) | HIF1ALIPGROCK1 | |
| SCHEMBL21189732 | 0.83 | AAK1 (0.36) | LRRK2HIF1AAAK1CDK4CCND1 | |
| SCHEMBL22858943 | 0.82 | HIF1A (0.36) | HIF1AAAK1LIPGROCK1 | |
| SCHEMBL21177598 | 0.82 | AAK1 (0.38) | CSF1RHIF1AAAK1DGAT1LIPG | |
| SCHEMBL21177651 | 0.82 | AAK1 (0.38) | CSF1RHIF1AAAK1DGAT1LIPG | |
| SCHEMBL18274795 | 0.79 | LPL (0.46) | CSF1RLIPG | |
| SCHEMBL25225416 | 0.79 | CSF1R (0.44) | CSF1RHIF1ALIPGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| CN-117069728-A | PI4KIII beta inhibitors | 葛兰素史克知识产权开发有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3740489-A1 | PI4KIIIBETA INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-11-25 | — | — | EP | disclosed |
| CN-111868063-A | PI4KIII beta inhibitors | 葛兰素史克知识产权开发有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | CSF1R 2246/4885LRRK2 795/4885HIF1A 2432/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | CSF1R 3127/4885LRRK2 1477/4885HIF1A 3002/4885 |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | CSF1R 2396/4885LRRK2 861/4885HIF1A 2573/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | CSF1R 2396/4885LRRK2 861/4885HIF1A 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.